Clinical overview on Lipoplatin™: A successful liposomal formulation of cisplatin

Expert Opinion on Investigational Drugs

Volumn 18, Issue 8, 2009, Pages 1197-1218

  Boulikas, Teni ^a,b  

^a Regulon Inc   (United States)

^b Regulon AE   (Greece)

Author keywords

Angiogenesis; Cisplatin; Lipoplatin ; Liposomes; Nanoparticle; NSCLC; Platinum transporters; Tumor targeting

Indexed keywords

CARBOPLATIN; CISPLATIN DERIVATIVE; DOXORUBICIN; EPTAPLATIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LIPOPLATIN; LOBAPLATIN; MITOPODOZIDE; NANOPARTICLE; NAVELBINE; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ALLERGY; ALOPECIA; ANEMIA; ASTHENIA; BACKACHE; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; EPIGASTRIC PAIN; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAIR LOSS; HEAD AND NECK CARCINOMA; HEAD AND NECK TUMOR; HUMAN; HYPOMAGNESEMIA; INFECTION; KIDNEY CARCINOMA; KIDNEY DISEASE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DISEASE; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PERIPHERAL NEUROPATHY; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; THROMBOCYTOPENIA; THROMBOSIS; TUMOR VASCULARIZATION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; CLINICAL TRIALS AS TOPIC; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIPOSOMES; MOLECULAR STRUCTURE; NANOPARTICLES; NEOPLASMS;

EID: 68049142557     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903114168     Document Type: Review

References (109)

1. Boulikas T, Pantos A, Bellis E, Christofis P. Designing platinum compounds in cancer: structures and mechanisms [review]. Cancer Therapy 2007;5:537-83. Available from: www.cancer-therapy.org
2. Boulikas T, Tsogas I. Microtubule-targeted antitumor drugs: chemistry, mechanisms and nanoparticle formulations. Gene Ther Mol Biol 2008;1:343-87. Available from: www.gtmb.org
3. Ribatti D. The discovery of antiangiogenic molecules: a historical review. Curr Pharm Des 2009;15:345-52
4. Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 2009;8:567-72
5. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15:1126-32
6. Al-Janadi A, Chandana SR, Conley BA. Histone deacetylation : an attractive target for cancer therapy? Drugs R D 2008;9:369-83
7. Emanuele S, Lauricella M, Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications [review]. Int J Oncol 2008;33:637-46
8. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008;26:3785-90
9. Sakamoto-Hojo ET, Balajee AS. Targeting poly (ADP) ribose polymerase I (PARP-1) and PARP-1 interacting proteins for cancer treatment. Anticancer Agents Med Chem 2008;8:402-16
10. Abreu PA, Dellamora-Ortiz G, Leão-Ferreira LR, et al. DNA methylation: a promising target for the twenty-first century. Expert Opin Ther Targets 2008;12:1035-47
11. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008;123:8-13
12. Boulikas T. Status of gene therapy in 1997: molecular mechanisms, disease targets, and clinical applications. Gene Ther Mol Biol 1998;1:1-172
13. Bachtarzi H, Stevenson M, Fisher K. Cancer gene therapy with targeted adenoviruses. Expert Opin Drug Deliv 2008;5:1231-40
14. Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 2004;12:3-12
15. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumor agents. Nature 1969;222:385-6
16. Sorenson C, Eastman A. Mechanism of cis-diamminedichloroplatinum (11)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 1988;48:4484-8
17. Garcia-del-Muro X, Maroto P, Gumà J, et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol 2008;26:5416-21
18. Hanigan MH, Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Therapy 2003;1:47-61
19. Harmers FP, Gispen WH, Neijt JP. Neurotoxic side-effects of cisplatin. Eur J Cancer 1991;27:372-6
20. Humes HD. Insights into ototoxicity. Analogies to nephrotoxicity. Ann NY Acad Sci 1999;884:15-18
21. Kitada N, Takara K, Minegaki T, et al. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother Pharmacol 2008;62:577-84
22. Stathopoulos GP, Boulikas T, Vougiouka M, et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep 2005;13:589-95
23. Gabizon A, Tzemach D, Mak L, et al. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 2002;10:539-48
24. Lasic DD, Martin FJ, Gabizon A, et al. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1991;1070:187-92
25. Yuan F, Leunig M, Huang SK, et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994;54:3352-6
26. Huang SK, Martin FJ, Jay G, et al. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 1993;143:10-4
27. Martin F, Boulikas T. The challenge of liposomes in gene therapy. Gene Ther Mol Biol 1998;1:173-214
28. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-6
29. Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 2005;25:3031-40
30. Boulikas T. Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin™. Lipoplatin™ as a chemotherapy and antiangiogenesis drug. Cancer Ther 2007;5:351-76
31. Veal GJ, Griffin MJ, Price E, et al. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer 2001;84:1029-35
32. White SC, Lorigan P, Margison GP, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 2006;95:822-8
33. Meerum Terwogt JM, Groenewegen G, Pluim D, et al. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol 2002;49:201-10
34. Vokes EE, Gordon GS, Mauer AM, et al. A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung cancer. Clin Lung Cancer 2000;2:128-32
35. Kim ES, Lu C, Khuri FR, et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001;34:427-32
36. Rosenthal DI, Yom SS, Liu L, et al. A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs 2002;20:343-9
37. Harrington KJ, Lewanski CR, Northcote AD, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 2001;12:493-6
38. Matsumoto S, Tanaka T, Kurokawa H, et al. Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin. Anticancer Res 2007;27:2209-16
39. Song IS, Savaraj N, Siddik ZH, et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004;3:1543-9. Erratum in: Mol Cancer Ther 2005;4:864
40. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24:1227-51
41. Yonezawa A, Masuda S, Yokoo S, et al. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006;319:879-86
42. Plasencia C, Martínez-Balibrea E, Martinez-Cardús A, et al. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol 2006;29:225-35
43. Safaei R, Larson BJ, Cheng TC, et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 2005;4:1595-604
44. Rabik CA, Maryon EB, Kasza K, et al. Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol 2009;64:133-42
45. Zisowsky J, Koegel S, Leyers S, et al. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 2007;73:298-307
46. Owatari S, Akune S, Komatsu M, et al. Copper-transporting P-Type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res 2007;67:4860-8
47. Choi MK, Kim DD. Platinum transporters and drug resistance. Arch Pharm Res 2006;29:1067-73
48. Negoro K, Yamano Y, Nakashima D, et al. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line. Oncol Rep 2009;21:443-9
49. Yokoo S, Masuda S, Yonezawa A, et al. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos 2008;36:2299-306
50. Zhang S, Lovejoy KS, Shima JE, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006;66:8847-57
51. Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 2008;7:3247-55
52. Acehan D, Jiang X, Morgan DG, et al. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell 2002;9:423-32
53. Wei Q, Dong G, Franklin J, Dong Z. The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 2007;72:53-62
54. Zhu J, Yang Y, Wu J. Bcl-2 cleavages at two adjacent sites by different caspases promote cisplatin-induced apoptosis. Cell Res 2007;17:441-8
55. Villedieu M, Briand M, Duval M, et al. Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21(WAF1/CIP1), Bcl-2 and Bcl-x(L) expression. Gynecol Oncol 2007;105:373-84
56. Nehmé A, Baskaran R, Aebi S, et al. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res 1997;57:3253-7
57. Han Z, Hong L, Wu K, et al. Reversal of multidrug resistance of gastric cancer cells by downregulation of Akt1 with Akt1 siRNA. J Exp Clin Cancer Res 2006;25:601-6
58. Villar J, Quadri HS, Song I, et al. PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization. Cancer Res 2009;69:102-10
59. Devarajan P, Tarabishi R, Mishra J, et al. Low renal toxicity of Lipoplatin compared to cisplatin in animals. Anticancer Res 2004;24:2193-200
60. Marr AK, Kurzman ID, Vail DM. Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs. Am J Vet Res 2004;65:1474-8
61. Fedier A, Poyet C, Perucchini D, et al. MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal. Anticancer Drugs 2006;17:315-23
62. Fedier A, Erdmann R, Boulikas T, Fink D. Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner. Int J Oncol 2006;29:1303-10
63. Arienti C, Tesei A, Ravaioli A, et al. Activity of lipoplatin in tumor and in normal cells in vitro. Anticancer Drugs 2008;19:983-90
64. Froudarakis ME, Pataka A, Pappas P, et al. Phase 1 trial of Lipoplatin and gemcitabine as a second-line chemotherapy in patients with non-small cell lung carcinoma. Cancer 2008;113:2752-60
65. Karpathiou G, Argiana E, Koutsopoulos A, Froudarakis ME. Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with Lipoplatin and gemcitabine. Oncology 2007;73(5-6):426-9
66. Stathopoulos GP, Boulikas T, Rigatos SK, et al. Liposomal cisplatin combined with gemcitabine in pretreated advanced cancer patients. Phase I-II study. Ann Oncol 2002;13:25
67. Stathopoulos GP, Androulakis N, Souglakos J, et al. Present treatment and future expectations in advanced pancreatic cancer. Anticancer Res 2008;28:1303-8
68. Stathopoulos GP, Boulikas T, Vougiouka M, et al. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol Rep 2006;15:1201-4
69. Available from: http://www.emea.europa.eu/pdfs/human/comp/opinion/ 16785007en.pdf
70. Mylonakis N, Athanasiou A, Ziras N, et al. Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as 1st line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer (NSCLC). Lung Cancer 2009 [In Press]
71. Farhat FS, Nasser A, Ibrahim K, et al. Preliminary results of a phase II study of Lipoplatin (Liposomal Cisplatin) - Vinorelbine combination as first line treatment in HER2/neu negative advanced breast cancer [abstract # 550699]. 31st Annual San Antonio Breast Cancer Symposium: 2008
72. Anevlavis S, Pataka A, Kouliatsis G, et al. A phase II trial of Lipoplatin-gemcitabine in patients with advanced NSCLC: preliminary results. Eur Respir J 2008;32:762s
73. Koukourakis MI, Giatromanolaki A, Pitakoudis M, et al. Concurrent liposomal cisplatin (Lipoplatin™), 5-Fluorouracil and?T. Concurrent liposomal cisplatin (Lipoplatin Radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study. Submitted
74. Skarlatos J, Kosma L, Koukourakis M, et al. Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. Int J Colorectal Dis 1996;11:206-10
75. Boulikas T, Mylonakis N, Sarikos G, et al. Superiority of Lipoplatin™ plus gemcitabine compared to cisplatin plus gemcitabine as first-line treatment against NSCLC: Preliminary results of a randomized, multicenter phase III trial. ASCO Abstract ID: 33204 (1-5 June 2007, Chicago, Illinois, USA)
76. Kosmas C, Angel J, Athanasiou A, et al. Interim Phase III analysis of Lipoplatin plus Gemcitabine versus Cisplatin plus Gemcitabine in advanced NSCLC. Abstract number: E15-1858. Submitted to ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin, 20-24 Sept 2009
77. Kim SW, Suh C, Lee SD, et al. Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2003;41:221-6
78. Rigas JR. Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 2004;9(Suppl 2):16-23
79. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005;23:3125-37
80. Stathopoulos GP, Michalopoulou P, Antoniou D, et al. Liposomal cisplatin and paclitaxel versus cisplatin and paclitaxel in advanced NSCLC. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25:7684
81. Stathopoulos GP, Antoniou D, Dimitroulis J, et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer. Submitted
82. Jehn CF, Boulikas T, Kourvetaris A, et al. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. Anticancer Res 2007;27:471-5
83. Jehn CF, Boulikas T, Kourvetaris A, et al. First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res 2008;28:3961-4
84. Ginsberg MS, Grewal RK, Heelan RT. Lung cancer. Radiol Clin North Am 2007;45:21-4
85. Crinò L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997;15:297-303
86. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
87. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
88. Gao G, Jiang J, Liang X, et al. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer. Lung Cancer 2009 In Press
89. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51
90. Tassinari D, Carloni F, Santelmo C, et al. Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature. Rev Recent Clin Trials 2009;4(1):27-33
91. Kosmas C, Tsavaris N, Syrigos K, et al. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol 2007;59:51-9
92. Felip E, Rosell R. Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). Ther Clin Risk Manag 2008;4:579-85
93. Yokoo S, Yonezawa A, Masuda S, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007;74:477-87
94. Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 2006;44:1173-83
95. Gregoriadis G, McCormack B, Obrenovic M, et al. Vaccine entrapment in liposomes. Methods 1999;19:156-62
96. Soni PN, Brown D, Saffie R, et al. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection. Hepatology 1998;28:1402-10
97. Zhang L, Granick S. How to stabilize phospholipid liposomes (using nanoparticles). Nano Lett 2006;6:694-8
98. Drummond DC, Noble CO, Guo Z, et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006;66:3271-7
99. Martin F, Boulikas T. The challenge of liposomes in gene therapy. Gene Ther Mol Biol 1998;1:173-214
100. Gregoriadis G, Fernandes A, Mital M, McCormack B. Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics. Cell Mol Life Sci 2000;57:1964-9
101. Hitzman CJ, Elmquist WF, Wattenberg LW, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci 2006;95:1114-26
102. Li YY, Qian GS, Huang GJ, et al. Enhancement of antiangiogenic effects of human canstatin with a hypoxia-regulated transgene vector in lung cancer model. Cancer J 2006;12:136-46
103. Wang R, Zhang XW, Wang GQ, et al. Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin. Cancer Gene Ther 2006;13(10):940-7
104. Liang S, Lin T, Ding J, et al. Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. J Mol Med 2006;84:764-73
105. Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos I. Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. Anticancer Res 2006;26:1489-94
106. Stathopoulos GP, et al. A Phase I study of the liposomal Semliki Forest virus expressing the human IL-12 gene in cancer patients. In preparation
107. Ravaioli A, Papi M, Pasquini E, et al. Lipoplatin monotherapy: A phase II trial of second-line treatment of metastatic non-small-cell lung cancer. J Chemother 2009;21:86-90
108. Ranson M, Thatcher N. Paclitaxel: a hope for advanced non-small cell lung cancer? Expert Opin Investig Drugs 1999;8:837-48
109. Lazarioti F, Boulikas T. Diagnostic and Therapeutic Efficacy of Imaging Modalities in Non-Small Cell Lung Cancer (NSCLC): experience from a Phase III clinical study using tumor targeted Lipoplatin nanoparticles. Cancer Ther 2008;6:629-46. Available from: www.cancer-therapy.org